138 related articles for article (PubMed ID: 36640858)
21. Homoharringtonine suppresses tumor proliferation and migration by regulating EphB4-mediated β-catenin loss in hepatocellular carcinoma.
Zhu M; Gong Z; Wu Q; Su Q; Yang T; Yu R; Xu R; Zhang Y
Cell Death Dis; 2020 Aug; 11(8):632. PubMed ID: 32801343
[TBL] [Abstract][Full Text] [Related]
22. PEGylated long-circulating liposomes deliver homoharringtonine to suppress multiple myeloma cancer stem cells.
Li M; Shi F; Fei X; Wu S; Wu D; Pan M; Luo S; Gu N; Dou J
Exp Biol Med (Maywood); 2017 May; 242(9):996-1004. PubMed ID: 28056549
[TBL] [Abstract][Full Text] [Related]
23. Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms.
Yuan F; Li D; Li G; Cheng C; Wei X
Ann Transl Med; 2022 Apr; 10(8):490. PubMed ID: 35571387
[TBL] [Abstract][Full Text] [Related]
24. Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability.
Lee DM; Sun A; Patil SS; Liu L; Rao AV; Trent PT; Ali AA; Liu C; Rausch JL; Presutti LD; Kaczorowski A; Schneider F; Amankulor NM; Shuda M; Duensing A
Sci Rep; 2022 May; 12(1):8275. PubMed ID: 35585158
[TBL] [Abstract][Full Text] [Related]
25. Integrin α5 mediates intrinsic cisplatin resistance in three-dimensional nasopharyngeal carcinoma spheroids via the inhibition of phosphorylated ERK /caspase-3 induced apoptosis.
Ngaokrajang U; Janvilisri T; Sae-Ueng U; Prungsak A; Kiatwuthinon P
Exp Cell Res; 2021 Sep; 406(2):112765. PubMed ID: 34358523
[TBL] [Abstract][Full Text] [Related]
26. Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms.
Nguyen T; Parker R; Zhang Y; Hawkins E; Kmieciak M; Craun W; Grant S
BMC Cancer; 2018 Nov; 18(1):1129. PubMed ID: 30445933
[TBL] [Abstract][Full Text] [Related]
27. MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway.
Ling Q; Li F; Zhang X; Mao S; Lin X; Pan J; Ye W; Wei W; Qian Y; Hu C; Huang X; Wang J; Wang H; Huang J; Wang Y; Jin J
EBioMedicine; 2021 Jul; 69():103441. PubMed ID: 34166980
[TBL] [Abstract][Full Text] [Related]
28. Homoharringtonine Exerts an Antimyeloma Effect by Promoting Excess Parkin-Dependent Mitophagy.
Zhang Y; Huang N; Xu J; Zheng W; Cui X
Drug Des Devel Ther; 2020; 14():4749-4763. PubMed ID: 33177810
[TBL] [Abstract][Full Text] [Related]
29. Homoharringtonine synergy with oridonin in treatment of t(8; 21) acute myeloid leukemia.
Zhang W; Lu Y; Zhen T; Chen X; Zhang M; Liu P; Weng X; Chen B; Wang Y
Front Med; 2019 Jun; 13(3):388-397. PubMed ID: 30206768
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of alpha5 integrin decreases PI3K activation and cell adhesion of human colon cancers.
Murillo CA; Rychahou PG; Evers BM
Surgery; 2004 Aug; 136(2):143-9. PubMed ID: 15300173
[TBL] [Abstract][Full Text] [Related]
31. Nortriptyline induces mitochondria and death receptor-mediated apoptosis in bladder cancer cells and inhibits bladder tumor growth in vivo.
Yuan SY; Cheng CL; Ho HC; Wang SS; Chiu KY; Su CK; Ou YC; Lin CC
Eur J Pharmacol; 2015 Aug; 761():309-20. PubMed ID: 26086857
[TBL] [Abstract][Full Text] [Related]
32. [Synergistic effect of azacitidine with homoharringtonine by activating the c-MYC/DDIT3/PUMA axis in acute myeloid leukemia].
Li J; Huang YQ; Zi J; Song CH; Ge Z
Zhonghua Xue Ye Xue Za Zhi; 2023 Dec; 44(12):1001-1009. PubMed ID: 38503523
[No Abstract] [Full Text] [Related]
33. The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation.
Jin Y; Lu Z; Cao K; Zhu Y; Chen Q; Zhu F; Qian C; Pan J
Mol Cancer Ther; 2010 Jan; 9(1):211-23. PubMed ID: 20053766
[TBL] [Abstract][Full Text] [Related]
34. Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies.
Roskoski R
Pharmacol Res; 2021 Jun; 168():105579. PubMed ID: 33774181
[TBL] [Abstract][Full Text] [Related]
35. Homoharringtonine sensitizes pancreatic cancer to erlotinib by direct targeting and miRNA-130b-3p-mediated EphB4-JAK2-STAT3 axis.
Sarwar A; Zhu Z; Zhu M; Tang X; Su Q; Yang T; Tang W; Zhang Y
J Pharm Pharmacol; 2023 Oct; 75(10):1294-1309. PubMed ID: 37463100
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-124-3p suppresses cell migration and invasion by targeting ITGA3 signaling in bladder cancer.
Wang JR; Liu B; Zhou L; Huang YX
Cancer Biomark; 2019; 24(2):159-172. PubMed ID: 30614803
[TBL] [Abstract][Full Text] [Related]
37. MAP30 protein from Momordica charantia is therapeutic and has synergic activity with cisplatin against ovarian cancer in vivo by altering metabolism and inducing ferroptosis.
Chan DW; Yung MM; Chan YS; Xuan Y; Yang H; Xu D; Zhan JB; Chan KK; Ng TB; Ngan HY
Pharmacol Res; 2020 Nov; 161():105157. PubMed ID: 32814169
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-485-5p targets keratin 17 to regulate oral cancer stemness and chemoresistance via the integrin/FAK/Src/ERK/β-catenin pathway.
Jang TH; Huang WC; Tung SL; Lin SC; Chen PM; Cho CY; Yang YY; Yen TC; Lo GH; Chuang SE; Wang LH
J Biomed Sci; 2022 Jun; 29(1):42. PubMed ID: 35706019
[TBL] [Abstract][Full Text] [Related]
39. Sialidase NEU1 suppresses progression of human bladder cancer cells by inhibiting fibronectin-integrin α5β1 interaction and Akt signaling pathway.
Zhou X; Zhai Y; Liu C; Yang G; Guo J; Li G; Sun C; Qi X; Li X; Guan F
Cell Commun Signal; 2020 Mar; 18(1):44. PubMed ID: 32164705
[TBL] [Abstract][Full Text] [Related]
40. Homoharringtonine stabilizes secondary structure of guanine-rich sequence existing in the 5'-untranslated region of Nrf2.
Kang JS; Lee J; Nam LB; Yoo OK; Pham KT; Duong TH; Keum YS
Bioorg Med Chem Lett; 2019 Aug; 29(16):2189-2196. PubMed ID: 31270017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
